Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CENTRAL: Early Conversion to Everolimus in Renal Transplant
NCT00634920Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2008
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial of everolimus in kidney transplant rejection (2 arms), sponsored by Novartis. Primary endpoint: Measured Glomerular Filtration Rate at 12 months. Started Mar 2008; status: completed.
02
Drugs
everolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00634920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00634920.